Estimating health state utilities associated with a rare disease: Familial chylomicronemia syndrome (FCS).

Aims: Familial Chylomicronemia Syndrome (FCS) is a rare genetic disorder with no currently approved therapies. Treatments are in development, and cost-utility analyses will be needed to examine the...